[1] WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV[EB/OL]. (2015-09-01)[2023-08-23]. https://www.who.int/publications/i/item/9789241509565. [2] Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men[J]. Sci Transl Med, 2012, 4(151): 151, 125. [3] Molina JM, Capitant C, Spire B, et al.On-demand preexposure prophylaxis in men at high risk for HIV-1 infection[J]. N Engl J Med, 2015, 373(23): 2237-2246. [4] Grant RM, Lama JR, Anderson PL, et al.Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men[J]. N Engl J Med, 2010, 363(27): 2587-2599. [5] Devarajan S, Sales JM, Hunt M, et al.PrEP and sexual well-being: A qualitative study on PrEP, sexuality of MSM, and patient-provider relationships[J]. AIDS Care, 2020, 32(3): 386-393. [6] 国家卫生健康委,中央宣传部,中央政法委,等. 多部门关于印发遏制艾滋病传播实施方案(2019—2022年)的通知[EB/OL]. (2019-09-11)[2023-08-23]. http://www.gov.cn/xinwen/2019-10/13/content_5439036.htm. [7] Li J, Peng L, Gilmour S.et al.A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China[J]. BMC Infect Dis, 2018, 18(1): 600. [8] Huang Y, Tian R, Zhou Z, et al.HIV pre-exposure prophylaxis use on a global scale among men who have sex with men: A systematic review and meta-analysis[J]. AIDS Patient Care STDS, 2023, 37(4): 159-191. [9] Cui S, Ding H, Huang X, et al.Factors influencing clinicians' willingness to prescribe pre-exposure prophylaxis for persons at high risk of HIV in China: Cross-sectional online survey study[J]. JMIR Public Health Surveill, 2021, 7(6): e24235. [10] Sell J, Chen R, Huber C, et al.Primary care provider HIV PrEP knowledge, attitudes, and prescribing habits: A cross-sectional survey of late adopters in rural and suburban practice[J]. J Prim Care Community Health, 2023, 14: 1-8. [11] Wu Y, Xie L, Meng S, et al.Mapping potential pre-exposure prophylaxis users onto a motivational cascade: Identifying targets to prepare for implementation in China[J]. LGBT Health, 2019, 6(5): 250-260. [12] Mullins TLK, Zimet G, Lally M, et al.HIV care providers' intentions to prescribe and actual prescription of pre-exposure prophylaxis to at-risk adolescents and adults[J]. AIDS Patient Care STDS, 2017, 31(12): 504-516. [13] Mayer KH, Agwu A, Malebranche D.Barriers to the wider use of pre-exposure prophylaxis in the United States: A narrative review[J]. Adv Ther, 2020, 37(5): 1778-1811. [14] Holloway IW, Dougherty R, Gildner J, et al.Brief report: PrEP uptake, adherence, and discontinuation among California YMSM using Geosocial networking applications[J]. J Acquir Immune Defic Syndr, 2017, 74(1): 15-20. [15] Fang WY, Bongani I, Mphoyi, et al. Efficacy, Adherence and Side Effects of PrEP for HIV-1 Prevention[J]. Int J Biol, 2019, 11(4): 80-87. [16] Sun Z, Gu Q, Dai Y, et al.Increasing awareness of HIV pre-exposure prophylaxis (PrEP) and willingness to use HIV PrEP among men who have sex with men: A systematic review and meta-analysis of global data[J]. J Int AIDS Soc, 2022, 25(3): e25883. [17] Cao W, You X, Li J, et al.Same-sex behavior disclosure to health care providers associated with greater awareness of pre-exposure prophylaxis[J]. BMC Public Health, 2021, 21(1): 2243. [18] Sun Y, Lu H, Ye J, et al.Awareness and use of HIV pre-exposure prophylaxis and factors associated with awareness among MSM in Beijing, China[J]. Sci Rep, 2023, 13(1): 554. |